Stock BLRX BIOLINERX LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Equities

BLRX

IL0011015182

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease
AQ
BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease
CI
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
AQ
Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
PU
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology
CI
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
PR
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
AQ
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
PU
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
CI
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
PR
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
CI
BioLineRx Announces $6 Million Registered Direct Offering
AQ
BioLineRx Shares Fall After $6 Million Registered Direct Offering
MT
BioLineRx : Form 20-F/A (Amendment No. 1
PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
AQ
BioLineRx : Annual Report on Form 20-F FOR 2023
PU
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLRX Stock
  4. BLRX Stock
  5. News BioLineRx Ltd.